期刊文献+

Survivin、Smad4/dpc4、APC基因在大肠腺瘤和腺癌中的表达及意义 被引量:3

The expression and significance of Survivin, Smad4/dpc4, APC gene in large intestinal adenoma and adenocarcinoma
原文传递
导出
摘要 目的 探讨Survivin、Smad4/dpo4、APC基因在大肠腺瘤、腺癌中的表达及意义.方法 采用免疫组化SP法检测40例正常大肠组织、80例腺瘤、80例腺癌中三种基因表达情况.结果 Survivin基因在正常大肠组织、腺瘤、腺癌中阳性表达率分别为0、35.0%、75.0%;Smad4基因为100%、95.0%、78.8%;APC为100%、80.0%、45.0%.结论 Survivin基因检测可以作为大肠癌早期诊断、观察疗效和监测肿瘤术后复发、转移等生物学行为的一个新指标.Smad4基因突变或缺失不仅诱导大肠癌的发生还促进其发展.检测APC基因突变,有助于对肿瘤病因学、发病机制及早期诊断的研究. Objective To observe the solo-allied expression of Survivin, Smad4/dpc4 and APC gene, and study the relationship between the three genes and biological behavior of colorectal cancer. Methods The expressions of Survivin, Smad4/dpc4 and APC gene were detected by SP immunohistochem-istry among the cases from 40 eu-intestine ,80 large intestinal adenoma and 80 CRC. Results The positive rate of survivin protein in the eu-intestine, the large intestinal adenoma and CRC was 0,35.0% ,75.0% , respectively. The positive rate of Smad4/dpc4 protein was 100% , 95. 0% , 78. 8% , and the positive rate of APC protein was 100% ,80.0% ,45.0% , respectively. In the eu-intestine, APC + Smad4/dpc4 Z- expressed in 40 cases, with the incidence of 100%. In the large intestinal adenoma, APC + Smad4 expressed in 38 patients, with the incidence of 47. 5% , and the three genes expressed in 29 patients with the incidence of 23. 8%. In the CRC, two genes expressed in 57 patients, with the incidence of 71. 3% , and three genes expressed in 28 patients, with the incidence of 35.0%. Conclusion The detection of survivin was a new indicator in early diagnosis of CRC. It was significant in the diagnosis of CRC that energetic search for the positive rate level realm of survivin. The catastrophe or absence of Smad4/dpc4 gene not only induced the genesis of CRC but also encouraged its growth. Smad4/dpc4 was ant- carcinomatous gene intimately correlated to the CRC. Detection of APC gene had very important significance, it could be helpful to conduct the research of tumorous aetiology, nosogenesis and early diagnosis. The allied detection of Survivin, Smad4/dpc4, APC gene played a very important role in early diagnosing and healing the CRC.
出处 《中国医师杂志》 CAS 2010年第5期625-628,共4页 Journal of Chinese Physician
关键词 微管相关蛋白质类/生物合成 DNA结合蛋白质类/生物合成 腺瘤状结肠息肉蛋 白质/生物合成 肠肿瘤/代谢 腺瘤/代谢 腺癌/代谢 Microtubule-associated proteins/BI DNA-binding proteins/BI Adenomatous polypo-sis coli protein/BI Intestinal neoplasms/ME Adenoma/ME Adenocarcinoma/ME
  • 相关文献

参考文献8

  • 1Steinert R,Buschmann T,van der Linden M,et al.The role of proteomics in the diagnosis and outcome prediction in colorectal cancer.Technol Cancer Res Treat,2002,1:297-304. 被引量:1
  • 2Zhang ZS,Zhang YL.Progress in research of colorectal cancer in China.Shijie Huaren Xiaohua Zazhi,2001,9:489-494. 被引量:1
  • 3Conway EM,Pollefeyt S,Steiner-Mosonyi M,et al.Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.Gastroenterology,2002,123:619-631. 被引量:1
  • 4Sarela Al,Macadam RC,Farmery SM,et al.Exprssion of the an-ti-apoptosis gene survivin predicts death from recurrent colorectal carcinoma.Cancer Res Clin Oncol,2000,46(5):645-650. 被引量:1
  • 5Rodel F,Hoffmann J,Grabenbauer GG,et al.High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.Strahlenther Onkol,2002,178:426-435. 被引量:1
  • 6Salovaara R,Roth S,Loukola A,et al.Frequent loss of Smad4/ dpc4 protein in colorectal cancers.Gut,2002,51:56-59. 被引量:1
  • 7Nichloas JP,Eric PW,Julie B,et al.Clinical cancer advances 2009:Major research advances in cancer treatment,prevention,and screening-a report from the American Society of Clinical Oncology.J Clin Oncol,2009,27:6052-6069. 被引量:1
  • 8刘荫华,徐玲.提倡诊断方法优先 提高直肠癌治疗水平[J].中华外科杂志,2010,48(7):481-483. 被引量:5

二级参考文献13

  • 1NCCN直肠癌临床实践指南(中国版)专家组.直肠癌临床实践指南(中国版-2009).[2009-12—14].http://www.nccn—asia.org/pdf/2009_Rectal_Cancer_Ch_m.pdf. 被引量:1
  • 2The NSABP Foundation, Inc. NSABP Clinical Trials Overview. [ 2009-12-18 ]. http ://www. nsabp. pitt. edu/NSABP_Protocols, asp. 被引量:1
  • 3Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum,2005,48 : 411-423. 被引量:1
  • 4Karapetis CS, Khambata FS, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med ,2008,359 : 1757-1765. 被引量:1
  • 5Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol,2008,26:374-379. 被引量:1
  • 6Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med ,2009,360 : 1408-1418. 被引量:1
  • 7中国抗癌协会临床肿瘤学协作专业委员会.基因检测大肠癌,靶向治疗个体化.[2009-4-2].http://news.csco.net.cn/class/detail.asp?u=296. 被引量:1
  • 8Zubrod CG, Schneiderman SM, Frei E, et al. Appraisal of methodsfor the study of chemotherapy of cancer in man: Comparativetherapeutic trial of nitrogen mustard and thiophosphamide. J Chronic Dis, 1960,11:7-33. 被引量:1
  • 9Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981,47:207-214. 被引量:1
  • 10Therasse P, Arbuck SG, Eisenhaner EA,et al. New guidelines to evaluation the response to treatment in solid tumors. J Natl Cancer Inst, 2000,92:205-216. 被引量:1

共引文献4

同被引文献41

引证文献3

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部